- Home
- REPL vs LENZ Comparison
REPL vs LENZ Comparison
Compare REPL & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- LENZ
- Stock Information
- Founded
- REPL 2015
- LENZ 2019
- Country
- REPL United States
- LENZ United States
- Employees
- REPL 331
- LENZ N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- LENZ Medicinal Chemicals and Botanical Products
- Sector
- REPL Health Care
- LENZ Health Care
- Exchange
- REPL Nasdaq
- LENZ Nasdaq
- Market Cap
- REPL 1.1B
- LENZ 679.4M
- IPO Year
- REPL 2018
- LENZ 2021
- Fundamental
- Price
- REPL $13.98
- LENZ $23.49
- Analyst Decision
- REPL Strong Buy
- LENZ Strong Buy
- Analyst Count
- REPL 6
- LENZ 6
- Target Price
- REPL $19.83
- LENZ $35.40
- AVG Volume (30 Days)
- REPL 610.9K
- LENZ 98.3K
- Earning Date
- REPL 02-12-2025
- LENZ 11-06-2024
- Dividend Yield
- REPL N/A
- LENZ 60.66%
- EPS Growth
- REPL N/A
- LENZ N/A
- EPS
- REPL N/A
- LENZ N/A
- Revenue
- REPL N/A
- LENZ N/A
- Revenue This Year
- REPL N/A
- LENZ N/A
- Revenue Next Year
- REPL $1,065.54
- LENZ N/A
- P/E Ratio
- REPL N/A
- LENZ N/A
- Revenue Growth
- REPL N/A
- LENZ N/A
- 52 Week Low
- REPL $4.92
- LENZ $2.57
- 52 Week High
- REPL $17.00
- LENZ $38.93
- Technical
- Relative Strength Index (RSI)
- REPL 55.54
- LENZ 35.48
- Support Level
- REPL $13.40
- LENZ $24.01
- Resistance Level
- REPL $14.59
- LENZ $25.90
- Average True Range (ATR)
- REPL 0.84
- LENZ 1.08
- MACD
- REPL -0.02
- LENZ 0.02
- Stochastic Oscillator
- REPL 66.52
- LENZ 9.02
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
About LENZ LENZ Therapeutics Inc. Common Stock
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.